In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.

@article{Jonge2012InVC,
  title={In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.},
  author={Hylke de Jonge and Henri{\"e}tte de Loor and Kristin Verbeke and Yves F Ch Vanrenterghem and Dirk Kuypers},
  journal={Clinical pharmacology and therapeutics},
  year={2012},
  volume={92 3},
  pages={
          366-75
        }
}
Tacrolimus is metabolized by CYP3A4 and CYP3A5 and is characterized by a narrow therapeutic index and highly variable pharmacokinetics. This cross-sectional study in 59 renal transplant patients investigated the relationship among in vivo CYP3A4 activity (assessed using midazolam as a drug probe), CYP3A5 genotype on the one hand, and tacrolimus pharmacokinetics on the other hand, taking into account other potential determinants of tacrolimus disposition. In vivo CYP3A4 activity and CYP3A5… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 44 CITATIONS, ESTIMATED 52% COVERAGE

83 Citations

051015'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 83 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 60 REFERENCES

A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1’-hydroxymidazolam and 4-hydroxymidazolam in human plasma

  • H. de Loor, H. de Jonge, K. Verbeke, Y. Vanrenterghem, D. R. Kuypers
  • Biomed. Chromatogr
  • 2011

results from a multicenter kidney transplant consortium

  • P. A. et al. Jacobson, DeKAF Investigators. Novel polymorphisms associated with concentrations
  • Transplantation 91, 300–308
  • 2011

2-year results from the BENEFIT and BENEFIT-EXT studies

  • Larsen, C. P. et al. Belatacept-based regimens versus a cyclo recipients
  • Transplantation 90, 1528–1535
  • 2010

Similar Papers

Loading similar papers…